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Abstract ß-adrenergic receptor kinase (ßARK-1 or GRK2) is a 
key regulatory protein involved in the regulation of G-protein-
coupled receptors which associates with microsomal and plasma 
membranes, ßy subunits of G-proteins have been suggested to 
mediate agonist-dependent membrane translocation of ßARK, 
but their possible role in maintaining the complex subcellular 
distribution of the kinase is not known. In this study we show that 
lovastatin-mediated inhibition of Gy subunits isoprenylation in 
HEK-293 cells stably transfected with ßARKl leads to a 
significant release of Gß subunits to the cytosol without causing 
changes in total particulate ßARK or in the association of this 
kinase to plasma or microsomal membrane fractions. In addition, 
transient overexpression of mutant forms of Gy unable to become 
isoprenylated resulted in a marked sequestration of Gß to the 
soluble compartment, but caused no rearrangement in the 
distribution of cotransfected ßARK. These results indicate that 
anchoring of ßARK to cellular membranes under basal condi-
tions is independent of the availability of heterotrimeric G-
protein subunits. 
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1. Introduction 
ß-adrenergic receptor kinase (ßARK)1 is a ubiquitous ser-
ine-threonine kinase able to phosphorylate specifically the ag-
onist-bound form of several G-protein-coupled receptors 
(GPCR). ßARK belongs to a family of kinases termed 
GRKs (for G-protein-coupled receptor kinases) that have 
been shown to play a key role in the processes of desensi-
tization of seven transmembrane-spanning receptors 
[1-4]. ßARK-mediated phosphorylation triggers the associa-
tion to the receptor of a protein named ß-arrestin, which 
inhibits the receptor-mediated activation of G-proteins 
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thus bringing about the termination of the response [3,4]. 
Recent studies have also involved ßARK and ß-arrestin pro-
teins in the subsequent process of receptor internalization 
[5,6]. 
ßARK was initially described as a cytosolic enzyme able to 
transiently translocate to the plasma membrane in response to 
agonist stimulation [7,8]. Based on in vitro observations, ßy 
subunits of G-proteins have been suggested to play a role in 
ßARK translocation to the cell surface upon receptor activa-
tion [2,4]. In addition, we have recently reported that a sig-
nificant amount of the kinase can be found in association with 
intracellular microsomal membranes under basal, unstimu-
lated conditions by means of a high-affinity (Kd = 20 nM) 
binding to an unidentified microsomal anchoring protein [9]. 
ßy subunits have been shown to both interact with ßARK 
[10,11] and enhance several-fold the catalytic activity of 
ßARK towards different G-protein-coupled receptors [10,12]. 
Recent studies have mapped the ßy-binding domain to a C-
terminal region corresponding to amino acids 546-670 of the 
bovine ßARKl [13]. This region is also present in the ßARK2 
(GRK3) isoform. The fact that the highest sequence hetero-
geneity between GRK2 and GRK3 lies in their C-terminus 
may account for different binding affinities to Gßy subunits 
[14]. The Gßy-binding region partially overlaps with a pleck-
strin homology (PH) domain (amino acids 553-651) [15] 
which has been implicated in the association of the kinase 
to different kinds of lipids which may contribute to the regu-
lation of ßARK localization and activity [16,17]. The PH do-
main of ßARK could therefore represent a way of anchoring 
the kinase to intracellular membranes through protein-lipid 
or protein-protein interactions. 
Interestingly, it has been shown that although ßy dimers are 
the units responsible for ßARK activation, binding of this 
kinase to Gßy is achieved equally well when the whole G-
protein heterotrimer is used as a ligand [11], thus suggesting 
that G-proteins may play a role as general kinase anchors in 
different cellular membranes and experimental conditions. 
However, the fact that the microsomal-anchoring domain 
has been mapped to an N-terminal region of ßARK distinct 
from the ßy-binding segment suggests that proteins different 
from ßy subunits of G-proteins could also be involved in 
kinase attachment and in modulating ßARK subcellular dis-
tribution [9,18]. In this context, and considering that in situ 
studies have not been performed with full-length wild-type 
kinase regarding its association to G-proteins under basal 
conditions, we have investigated the effects of changes in 
membrane-bound Gßy subunits on the subcellular pattern of 
ßARK. Our results lend further support to the notion that the 
association of the kinase to different cellular membranes 
under basal situations is accomplished via additional anchor-
ing mechanisms. 
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2. Materials and methods 
2.1. Materials 
Human embryonic kidney EBNA-293 cells were obtained from In-
vitrogen Corporation. Lovastatin was kindly provided by Merck 
Sharp and Dohme (Rahway, NJ). Antibiotics were purchased from 
Calbiochem, sera from Gibco and culture plates from Costar. Anti-
bodies against G-protein ß and y subunits were obtained from Santa 
Cruz Biotechnology. Electrophoresis reagents were from Bio-Rad. All 
other reagents were of the highest purity available. 
2.2. Cell culture, transfection and treatments 
HEK-293 cells stably overexpressing bovine ßARKl were generated 
as described [6]. They were grown in monolayers over P-100 dishes 
previously coated with 10 ug/ml poly-L-lysine in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with 15% fetal calf serum 
and antibiotics (gentamicin 50 ug/ml, Streptomycin 0.01% and Peni-
cillin G 0.063%) together with hygromycin (0.25 mg/ml) and geneticin 
(0.2 mg/ml). Cells were grown to confluence in a water-saturated 
atmosphere at 37°C and 7% C0 2 . For cell treatment, lovastatin was 
converted to the lactone sodium salt as described [19], diluted to 10 
mM and kept frozen at —20°C until used. Cells were incubated for 48 
h in the presence of 15 uM lovastatin or vehicle as a control. 
For transient expression experiments, HEK-293 cells were trans-
fected with 2.5 ug/dish of pREP4-ßARK, that contained the full-
length form of bovine ßARKl cDNA, alone or in combination with 
diverse constructs of G-protein subunits, using the calcium phosphate 
precipitation method [20]. Mutant forms of Gyi or Gy2 subunits that 
are unable to become isoprenylated (pCMV-yx* or pcDM8.1-y2*, 18 
Ug/dish) were transiently overexpressed to specifically sequester endog-
enous Gß subunits to the cell cytosol [21]. In some experiments wild-
type Gß2 and Gy2 subunits (pcDNAI-Gß2 and pcDM8.1-Gy2, 9 ug/ 
dish of each construct) were also used [22,23]. All G-protein con-
structs were kindly donated by Dr. Melvin I. Simon (Caltech, Pasa-
dena). The amount of total DNA per dish was adjusted with empty 
vector. Transfection efficiency was 15-20% as assessed by indirect 
immunofluorescence using anti-ßARK antibodies [18]. Cells were har-
vested 36 h after transfection and processed as described below. 
37 kDa) were subjected to quantitation by densitometric analysis in a 
Molecular Dynamics Laser densitometer. 
3. Results and discussion 
With the aim to investigate the role played by heterotrimer-
ic G-proteins in maintaining the complex subcellular distribu-
tion of ß A R K in situ, we took advantage of the well-docu-
mented fact that the anchoring of Gy subunits to membranes 
is achieved by means of its isoprenyl moiety [24,25] to modify 
2.3. Subcellular fractionation 
Cell fractionation was performed by a modification of the method 
described in [18]. Briefly, cells were harvested and washed extensively 
with phosphate-buffered saline. The resulting cell pellet was «sus-
pended in 300 ul of lysis buffer (5 mM Tris-HCl (pH 7.5), 2 mM 
EDTA, aprotinin 8 ug/ml, phenylmethylsulphonyl fluoride 100 uM, 
and 100 ug/ml each of soybean trypsin inhibitor, bacitracin and ben-
zamidine) per dish and homogenized by two 30-s strokes in a Polytron 
PT 3000 apparatus. Unbroken cells and nuclei were sedimented by 
centrifugation (800 Xg, 4 min) and particulate plus soluble fractions 
were obtained by a single high-speed centrifugation step (230000Xg, 
40 min) in a Beckman TL100.1 ultracentrifuge. In some experiments, 
a crude plasma membrane pellet was obtained by centrifugation at 
12000Xg for 20 min at 4°C. A subsequent centrifugation step at 
230 000 X g for 45 min separated the crude microsomal membrane 
preparation and the soluble cytosolic fraction. To extract peripherally 
associated proteins, membrane fractions were resuspended and incu-
bated in 200 mM NaCl for 30 min at 4°C and recentrifuged in the 
same conditions [18]. 
2.4. Immunoblotting 
Western blots were performed as described [9]. Briefly, equal 
amounts of proteins from each cellular fraction were resolved by 
electrophoresis in 11% SDS-PAGE and blotted onto nitrocellulose 
filters in a Bio-Rad wet chamber electrotransfer apparatus following 
manufacturer's instructions. The upper part of the filter (molecular 
mass range 66-97 kDa) was then incubated with a polyclonal anti-
serum against recombinant ßARK (Ab9, 1:1000, kindly provided by 
Dr. J.L. Benovic, Thomas Jefferson Cancer Institute, Philadelphia, 
PA) or a purified polyclonal antiserum raised against a GST-
ßARK(50-145) fusion protein (Ab-FPl, 5 ug/ml). The lower part of 
the filter (molecular mass range 21^45 kDa) was incubated with M14 
anti-Gß common polyclonal antibody (5 ug/ml, Santa Cruz Biotech-
nology). Blots were developed by a chemiluminiscent method (ECL, 
Amersham) and bands corresponding to ßARK (80 kDa) or Gß (36-
Fig. 1. Effect of lovastatin treatment on the subcellular distribution 
of ßARK and G-protein ß subunits. HEK-293 cells stably trans-
fected with ßARKl were treated or not with the active form of lov-
astatin (15 uM) for 48 h. After cell lysis and centrifugation, the 
same amount of protein (60 ug) from particulate and soluble frac-
tions (prepared as described in Section 2) was resolved by 11% 
SDS-PAGE followed by blotting onto nitrocellulose membranes. 
The lower part of the blot was incubated with M14 anti-Gß anti-
body (5 ug/ml, panel A) and the upper part of the blot with anti-
ßARK Ab9 antibody (1:1000, panel B). The blots were developed 
and quantified by densitometric analysis. Data were referred to total 
cellular ßARK or Gß protein and results from 4-6 independent ex-
periments were subjected to statistical evaluation using unpaired 
Student's t test. *P<0.05 with respect to control cells. 
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the subcellular distribution of Gßy dimers in cultured cells. 
Lovastatin (a competitive inhibitor of hydroxymethylglutar-
yl-CoA reductase, a key enzyme in isoprenoid metabolism) 
has been shown to promote an important solubilization of 
heterotrimeric G-proteins in several systems [26-28]. In this 
line, we tested the effects of lovastatin treatment of HEK-293 
cells stably transfected with ßARK on the membrane associ-
ation of both endogenous Gß-protein and the kinase by West-
ern blot analysis of soluble and particulate fractions. ßARK 
overexpression does not lead to changes in the subcellular 
localization of the kinase compared to wild-type cells (data 
not shown). Fig. 1A shows that lovastatin caused a clear 
redistribution of Gß subunits from the particulate to the solu-
ble pool, where the percentage of total Gß-protein found in-
creased from 5 ± 2% in control cells to 25 ± 2% in treated cells. 
The corresponding decrease in the amount of G-proteins 
present in the particulate fraction (Fig. 1A) failed to provoke 
any significant impairment in the membrane association of 
ßARK, which displays a similar subcellular pattern of immu-
noreactivity in control and treated cells (Fig. IB). 
In a previous in vitro study [9] we have reported that re-
combinant ßARK is able to interact with a protein compo-
nent of microsomal membrane preparations via a new target-
ing domain located in the N-terminal region of the kinase, 
thus suggesting the involvement of anchoring proteins differ-
ent from Gßy subunits. To explore the possibility of a differ-
ential effect of lovastatin treatment on Gßy presence in the 
diverse cellular membranes, or a distinct involvement of Gßy 
subunits in kinase anchoring to the various cellular locations, 
a more detailed study was performed. Fig. 2 shows the 
amount of Gß subunits and ßARK protein present in different 
cellular fractions (cytosol, plasma membrane and microsomal 
membranes) in control and treated cells as visualized by West-
ern blot. A marked change in the amount of Gß subunits 
associated to both plasma and microsomal membranes is ob-
served (compare lanes — to + lovastatin under PM and MM) 
whereas an increase takes place in the soluble cytosolic com-
partment (that contained 48 ± 3% of total Gß in treated cells, 
mean ± SEM of three experiments). On the other hand, ßARK 
immunoreactivity in the different compartments revealed an 
unaltered distribution and, when normalized for total cellular 
protein, the distribution of kinase in the different subcellular 
fractions was in agreement with previously published data 
[18]. Our results indicate that important changes in the differ-
ent membrane pools of Gß subunits do not lead to a rear-
rangement of ßARK subcellular distribution in situ. In par-
ticular, the data regarding microsomal fractions are in 
agreement with previous in vitro studies showing that deple-
tion of approximately half the population of endogenous het-
erotrimeric G-proteins from crude microsomal membranes by 
alkaline extraction did not affect the ability of recombinant 
ßARK to associate to membranes [9], thus further arguing in 
favor of the implication of a new anchoring component. 
In order to rule out the possibility that lovastatin treatment 
could be exerting indirect, compensatory effects on ßARK 
membrane association by means of its actions on other iso-
prenylated cellular proteins, we used a more direct strategy to 
modify the ratio of soluble to particulated Gß subunits in 
cells. In this experimental approach, we cotransfected HEK-
293 cells with ßARKl constructs and mutant forms of Gy 
Fig. 2. Effect of lovastatin treatment on Gß subunits and ßARK distribution in different cellular fractions. Subcellular fractions of HEK-293 
cells stably expressing bovine ßARKl were obtained as specified in Section 2 from cells grown to confluence treated (+) or not (—) for 48 h 
with 15 uM lovastatin. For ßARK analysis, equal amounts (20 ug) of proteins from the cytosolic fraction (CYT) or extracted by 200 mM 
NaCl treatment from either plasma membrane (PM) or microsomal membranes (MM) fractions were resolved by 11% SDS-PAGE. Immuno-
blot analysis was performed using an affinity-purified anti-ßARK antibody (anti-GST-ßARK(50-145), 5 |ig/ml). For Gß quantitation, equal 
amounts (20 ug) of cytosol (CYT) or plasma membrane (PM) or microsomal membrane (MM) fractions containing the proteins that remained 
attached to the membranes after salt extraction, were resolved, blotted and analyzed with anti-Gßcommon M14 antibody (5 ug/ml). The migra-
tion of ßARK and Gß is indicated by arrows and that of the molecular mass standards is shown in the left margin of the figure. Results are 
representative of three independent experiments. 
C. Murga et al.lFEBS Letters 409 (1997) 24-28 27 
Fig. 3. Effect of overexpression of isoprenylation-deficient Gy sub-
unit mutants (Gy") on the subcellular distribution of endogenous 
Gß subunits and cotransfected ßARKl in HEK-293 cells. HEK-293 
cells were transiently co-transfected with pREP4-ßARKl and either 
pCMV-yi*, pcDM8.1-Y2* or empty vector as a control. Cells were 
processed as described in Fig. 1. A representative blot is shown in 
panel A. The migration of ßARK and Gß-proteins is indicated by 
arrows. Panel B displays ratios of soluble to particulate protein as 
calculated from densitometric analysis of the blots. Data are means 
± SEM of three independent experiments. Significant differences 
were found for Gß ratios (*P<0.02) but not for those of ßARK 
(P = 0.924). 
subunits unable to become isoprenylated [21]. A marked 
transfer of Gß subunits from particulate (P) to soluble (S) 
fractions is visualized by Western blot analysis in cells co-
transfected with G72* (Fig. 3A) or Gyi* (not shown) mutant 
constructs and ßARK. A significant increase in the soluble 
versus particulate Gß ratio in the cells expressing y* subunit 
mutants is detected by densitometric analysis of the immuno-
blots (Fig. 3B, hatched bars). Again, such variation in Gß 
subunits caused no significant change in the ratio of soluble 
to particulated ßARK (Fig. 3A and open bars in Fig. 3B). 
Interestingly, when wild-type ß2 and 72 constructs were co-
transfected along with the kinase, the ratio of soluble versus 
particulated kinase decreased from 0.85 ±0.03 in control cells 
to 0.47 ± 0.04 in Gßy-transfected (means ± SEM of three ex-
periments), thus indicating an enhanced membrane associa-
tion of the kinase probably due to an increased availability 
of free Gßy dimers in the particulate pool. Since this situation 
would reflect the release of Gßy that takes place after receptor 
stimulation, our data suggest that, although not readily in-
volved in the association of ßARK to cellular membranes 
under basal conditions, Gßy subunits may play a role in ago-
nist-mediated targeting of the kinase to the membrane in in-
tact cells. It is also worth noting that a slight decrease in 
ßARK levels is observed in the cells expressing y* subunit 
mutants (Fig. 3A), thus raising the possibility that kinase ex-
pression or stability could be modulated in such experimental 
conditions. 
The results described in the present study provide evidence 
to support new types of cellular interactions for ßARK, in-
dependent from its association to G-protein ßy subunits. 
Although ßy binding to the C-terminal region of ßARK is 
well documented [29-31], the relevance of the association of 
the full-length kinase to Gßy in situ remained to be estab-
lished. The fact that additional ligands for ßARK have been 
recently described, including several types of phospholipids 
[16,32] and a microsomal protein component [9,18] suggest 
that complex mechanisms operate to govern the intracellular 
localization of ßARK. Our results strongly suggest that the 
association of the kinase to intracellular particulate pools 
under basal conditions is not predominantly accomplished 
by attachment to heterotrimeric G-protein subunits. It is pos-
sible that interactions with lipids may play a role in ßARK 
anchoring to cellular particulate fractions. However, it should 
be noted that anchoring of the kinase to microsomal mem-
branes in vitro is both heat and protease sensitive, and re-
quires a N-terminal domain of the kinase that does not in-
clude the reported lipid-binding PH domain [9]. Therefore, the 
association of ßARK with specific membrane-localized an-
choring proteins (as described for other protein kinases, re-
viewed in [33]) may represent an essential mechanism for reg-
ulating the localization and possibly the kinase activity of this 
key regulatory protein [9,17]. Further experimental efforts will 
be required to identify such anchoring protein(s) and its bio-
logical role in the complex regulation of ßARK localization 
and function. 
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